SEC Contract Filing

Filing Date: 2020-04-17

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex_181763.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_181763.htm</title>

	<!-- Generated by ThunderDome Portal - 4/17/2020 5:12:01 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>VIVEVE MEDICAL, INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:69.2%;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">April ___, 2020&nbsp; &nbsp; &nbsp; &nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Holder of Common Stock Purchase Warrant</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inducement Offer to Exercise Common Stock Purchase Warrants</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Dear Holder:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Viveve Medical, Inc. (the &#8220;<u>Company</u>&#8221;) is pleased to offer to you the opportunity to exercise all of the Series A Common Stock Purchase Warrants and/or the Series B Common Stock Purchase Warrants of the Company set forth on the signature page hereto (collectively, the &#8220;<u>Existing Warrants</u>&#8221;) currently held by you (the &#8220;<u>Holder</u>&#8221;). The Existing Warrants and the shares underlying the Existing Warrants (&#8220;<u>Existing </u><u>Warrant Shares</u>&#8221;) have been registered pursuant to registration statement Form S-1 (File No. 333-233639) (the &#8220;<u>Registration Statement</u>&#8221;) and were issued pursuant to that certain Underwriting Agreement, dated as of November 22, 2019 (the &#8220;<u>Underwriting </u><u>Agreement</u>&#8221;). The Registration Statement is currently effective and, upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance or sale, as the case may be, of the Existing Warrant Shares.<b> </b>Capitalized terms not otherwise defined herein shall have the meanings set forth in the Underwriting Agreement.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In consideration for exercising some or all of the Existing Warrants held by you and set forth on the signature page hereto (the &#8220;<u>Warrant Exercise</u>&#8221;), the Company hereby offers to issue you or your designees a new Series A-2/B-2 Common Stock Purchase Warrant to purchase up to a number of shares of Common Stock equal to <b>100</b><b>%</b> of the number of Warrant Shares issued pursuant to each Warrant Exercise, which New Warrant (as defined below) shall be substantially in the form of the Existing Warrants. The new Series A-2 Common Stock Purchase Warrants will be initially exercisable on the date of issuance, have a term of exercise of five (5) year thereafter, and an exercise price equal to $0.6371 (the &#8220;<u>New Series A Warrants</u>&#8221;). The new Series B-2 Common Stock Warrants will be initially exercisable on the date of issuance, have a term of exercise of 5 years thereafter, and an exercise price equal to $0.6371 (the &#8220;<u>New Series B Warrants</u>&#8221; and, collectively with the New Series A Warrants, the &#8220;<u>New Wa</u><u>rrants</u>&#8221;). <u><b>A Warrant Exercise shall be effected through the delivery by the Holder to the Company of a Notice of Exercise of the Existing Warrant.</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The original New Warrant certificates will be delivered within two Business Days following each Warrant Exercise pursuant to this letter agreement. Notwithstanding anything herein to the contrary, in the event a Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&#8220;<u>Beneficial Ownership Limitation</u>&#8221;) set forth in Section 2(e) of the Existing Warrants, the Company shall only issue such number of Existing Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number of Existing Warrant Shares permitted thereunder with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the Existing Warrants which shall be deemed prepaid thereafte